Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 7, 2012
Melanoma
Daniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
Douglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelines
Daniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal for Immunotherapy of Cancer
|
July 25, 2025
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2014
Melanoma, version 4.2014
Daniel G Coit, John A Thompson, Robert Andtbacka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Cancer Immunology Research
|
April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
The Lancet. Oncology
|
June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 7, 2012
Melanoma
Daniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
Douglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelines
Daniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal for Immunotherapy of Cancer
|
July 25, 2025
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2014
Melanoma, version 4.2014
Daniel G Coit, John A Thompson, Robert Andtbacka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Cancer Immunology Research
|
April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
The Lancet. Oncology
|
June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Page
of 11